SENTI BIOSCIENCES INC

Company Overview

Senti Biosciences (SNTI) is a clinical‑stage synthetic biology company developing gene‑circuit programmed cell and gene therapies that “sense, compute and respond.” Its lead internal programs are allogeneic CAR‑NK candidates SENTI‑202 (CD33/FLT3 logic‑gated, Phase 1; early data showed 2 of 3 low‑dose patients with CR and MRD‑negative status) and a partnered GPC3 program (SN301A/SENTI‑301A) being developed in China that has encountered dose‑limiting toxicities and prompted enrollment pauses. The company is R&D‑focused, relies on external manufacturing (GeneFab) and partners (Celest, Spark, BlueRock) for development and potential milestone/royalty revenue, and operates with a small staff (~34 FTEs). Financially it is pre‑revenue with accelerating cash burn, a shrinking cash balance ($21.6M at 6/30/25) and management’s disclosure of substantial doubt about its ability to continue as a going concern.

Executive Compensation Practices

Compensation at Senti is likely weighted heavily toward equity and milestone‑linked awards rather than cash, reflecting its pre‑revenue, cash‑constrained profile; management noted materially lower stock‑based compensation in 2024 but approved an expanded equity incentive plan in H1 2025. Pay and realized value for executives will be closely tied to clinical and regulatory readouts (INDs, Phase transitions, safety profile, Orphan/RMAT designations) and to partnership or licensing milestones and manufacturing scale‑up successes that can generate non‑dilutive or milestone revenue. Given tight cash and ongoing financings (PIPEs, preferred conversions, ATM activity), base salaries may be modest and retention tools (time‑vested RSUs, performance‑based equity) and severance/change‑in‑control provisions are likely important. Companies in this stage also commonly include clawback or malus provisions tied to safety issues or material restatements; the recent SN301A safety signal increases the relevance of such safeguards.

Insider Trading Considerations

Insider trading behavior at Senti will be heavily influenced by liquidity constraints, recent financings and corporate actions (July 2024 1‑for‑10 reverse split, Dec 2024 PIPE of convertible preferred, March 2025 preferred‑to‑common conversion, and a H1 2025 ATM facility). Because executives receive much of their pay in equity and may exercise options to cover tax or personal liquidity needs, Form 4 sales around financing closings or immediately after equity grants are common and should be interpreted in context rather than as pure negative signals. Material clinical or regulatory events (Phase 1 data, IND/BLA submissions, safety pauses like the SN301A DLTs, Orphan Drug designations) create clear blackout periods and elevated insider‑trading risk; purchases by insiders during tense cash periods are comparatively high‑conviction signals. Monitor filings for 10b5‑1 plan disclosures, timing relative to trial readouts and partnership milestones, and any large insider sales that coincide with financings which may reflect dilution/liquidity dynamics rather than changes in confidence.